The commercially available rebamipide ophthalmic suspension (CA-REB) was approved\nfor clinical use in patients with dry eye; however, the residence time on the ocular surface for the\ntraditional formulations is short, since the drug is removed from the ocular surface through the\nnasolacrimal duct. In this study, we designed a novel sustained-release drug delivery system (DDS) for\ndry eye therapy by rebamipide nanoparticles. The rebamipide solid nanoparticle-based ophthalmic\nformulation (REB-NPs) was prepared by a bead mill using additives...................
Loading....